Immunic's lead asset, vidofludimus calcium, shows promise in MS trials, with positive interim results. See why I rate IMUX ...

Looking at Immunic, Inc.'s ( NASDAQ:IMUX ) insider transactions over the last year, we can see that insiders were ...

Immunic (NASDAQ:IMUX – Get Free Report) ‘s stock had its “buy” rating restated by analysts at D. Boral Capital in a report issued on Thursday,Benzinga reports.They presently have a $17.00 ...

Canva, the world's only all-in-one visual communication platform, today unveiled the Visual Suite 2.0 ? the company's biggest product launch since founding in 2012, reimagining how teams create, ...

NEW YORK, April 10, 2025 /PRNewswire/ -- Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule ...

Immunic ( (IMUX)) has shared an announcement. On April 9, 2025, Immunic, Inc. announced a securities purchase agreement with institutional and accredited investors for the issuance and sale of ...

Zeitverzögerung der Kursdaten: Deutsche Börsen +15 Min. NASDAQ +15 Min. NYSE +20 Min. AMEX +20 Min. Dow Jones +15 Min. Alle Angaben ohne Gewähr. Die Informationen auf dem Portal BörsenNEWS.de ...